- Home
- PSO vs QGEN Comparison
PSO vs QGEN Comparison
Compare PSO & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSO | QGEN |
|---|---|---|
| Founded | 1844 | 1986 |
| Country | United Kingdom | Netherlands |
| Employees | 17062 | N/A |
| Industry | Books | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.7B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | PSO | QGEN |
|---|---|---|
| Price | $16.46 | $42.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $45.76 |
| AVG Volume (30 Days) | 809.5K | ★ 2.7M |
| Earning Date | 02-27-2026 | 05-06-2026 |
| Dividend Yield | 2.36% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.26 | $8.18 |
| Revenue Next Year | $4.54 | $5.71 |
| P/E Ratio | ★ $14.05 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.02 | $32.53 |
| 52 Week High | $17.75 | $57.82 |
Technical Indicators
Market Signals| Indicator | PSO | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 57.46 |
| Support Level | $16.17 | $39.08 |
| Resistance Level | $17.70 | $42.33 |
| Average True Range (ATR) | 0.33 | 0.86 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 33.05 | 71.82 |
Price Performance
Historical ComparisonAbout PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualifications, testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and the publishing house Penguin, and is now focused on serving as an educational resource and testing provider.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).